Compare CABR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | TOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 16.4M |
| IPO Year | N/A | 2012 |
| Metric | CABR | TOVX |
|---|---|---|
| Price | $0.99 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 48.8K | ★ 23.1M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.16 |
| 52 Week High | $1.65 | $1.40 |
| Indicator | CABR | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 60.63 |
| Support Level | $0.78 | $0.18 |
| Resistance Level | $1.08 | $0.52 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 14.92 | 51.60 |
Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.